Abstract
SUGEN is developing SU-11248, an orally active inhibitor of platelet-derived growth factor tyrosine kinase (TK) and other TK signaling pathways, as a potential anticancer agent. By October 2003, phase III trials for gastrointestinal stromal tumors and renal cell carcinoma were underway.
MeSH terms
-
Animals
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Clinical Trials, Phase III as Topic
-
Drugs, Investigational / chemistry
-
Drugs, Investigational / pharmacology
-
Drugs, Investigational / therapeutic use*
-
Humans
-
Indoles / chemistry
-
Indoles / pharmacology
-
Indoles / therapeutic use*
-
Pyrroles / chemistry
-
Pyrroles / pharmacology
-
Pyrroles / therapeutic use*
-
Sunitinib
Substances
-
Antineoplastic Agents
-
Drugs, Investigational
-
Indoles
-
Pyrroles
-
Sunitinib